Literature DB >> 34993885

Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors.

Hiba Alzoubi1, Simone Minasi2, Francesca Gianno2,3, Manila Antonelli2, Francesca Belardinilli4, Felice Giangaspero2,3, Marie-Lise Jaffrain-Rea5,3, Francesca Romana Buttarelli6.   

Abstract

Neoplastic cells acquire the ability to proliferate endlessly by maintaining telomeres via telomerase, or alternative lengthening of telomeres (ALT). The role of telomere maintenance in pituitary neuroendocrine tumors (PitNETs) has yet to be thoroughly investigated. We analyzed surgical samples of 24 adult recurrent PitNETs (including onset and relapses for 14 of them) and 12 pediatric primary PitNETs. The presence of ALT was assessed using telomere-specific fluorescence in situ hybridization, methylation of telomerase reverse transcriptase promoter (TERTp) by methylation-specific PCR, and ATRX expression by immunohistochemistry. Among the adult recurrent PitNETs, we identified 3/24 (12.5%) ALT-positive cases. ALT was present from the onset and maintained in subsequent relapses, suggesting that this mechanism occurs early in tumorigenesis and is stable during progression. ATRX loss was only seen in one ALT-positive case. Noteworthy, ALT was observed in 3 out of 5 aggressive PitNETs, including two aggressive corticotroph tumors, eventually leading to patient's death. ALT-negative tumors (87.5%) were classified according to their low (29.2%), medium (50%), and high (8.3%) telomere fluorescence intensity, with no significant differences emerging in their molecular, clinical, or pathological characteristics. TERTp methylation was found in 6/24 cases (25%), with a total concordance in methylation status between onset and recurrences, suggesting that this mechanism remains stable throughout disease progression. TERTp methylation did not influence telomere length. In the pediatric cohort of PitNETs, TERTp methylation was also observed in 4/12 cases (33.3%), but no case of ALT activation was observed. In conclusion, ALT is triggered at onset and maintained during tumor progression in a subset of adult PitNETs, suggesting that it could be used for clinical purposes, as a potential predictor of aggressive behavior.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  ALT; ATRX; Pituitary neuroendocrine tumors; TERTp methylation; Telomere

Year:  2022        PMID: 34993885     DOI: 10.1007/s12022-021-09702-0

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  50 in total

1.  High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium.

Authors:  Adrian F Daly; Martine Rixhon; Christelle Adam; Anastasia Dempegioti; Maria A Tichomirowa; Albert Beckers
Journal:  J Clin Endocrinol Metab       Date:  2006-09-12       Impact factor: 5.958

Review 2.  Pediatric Pituitary Adenoma: Case Series, Review of the Literature, and a Skull Base Treatment Paradigm.

Authors:  Avital Perry; Christopher Salvatore Graffeo; Christopher Marcellino; Bruce E Pollock; Nicholas M Wetjen; Fredric B Meyer
Journal:  J Neurol Surg B Skull Base       Date:  2018-01-24

3.  Landscape of Genomic Alterations in Pituitary Adenomas.

Authors:  Wenya Linda Bi; Peleg Horowitz; Noah F Greenwald; Malak Abedalthagafi; Pankaj K Agarwalla; Wiliam J Gibson; Yu Mei; Steven E Schumacher; Uri Ben-David; Aaron Chevalier; Scott Carter; Grace Tiao; Priscilla K Brastianos; Azra H Ligon; Matthew Ducar; Laura MacConaill; Edward R Laws; Sandro Santagata; Rameen Beroukhim; Ian F Dunn
Journal:  Clin Cancer Res       Date:  2016-10-05       Impact factor: 12.531

Review 4.  A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal.

Authors:  C Villa; A Vasiljevic; M L Jaffrain-Rea; O Ansorge; S Asioli; V Barresi; L Chinezu; M P Gardiman; A Lania; A M Lapshina; L Poliani; L Reiniger; A Righi; W Saeger; J Soukup; M Theodoropoulou; S Uccella; J Trouillas; F Roncaroli
Journal:  Virchows Arch       Date:  2019-10-02       Impact factor: 4.064

5.  Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups.

Authors:  F G Davis; V Kupelian; S Freels; B McCarthy; T Surawicz
Journal:  Neuro Oncol       Date:  2001-07       Impact factor: 12.300

6.  Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors.

Authors:  Sylvia L Asa
Journal:  Endocr Pathol       Date:  2021-04-17       Impact factor: 3.943

Review 7.  Update on the Genetics of Pituitary Tumors.

Authors:  Sayka Barry; Márta Korbonits
Journal:  Endocrinol Metab Clin North Am       Date:  2020-09       Impact factor: 4.741

Review 8.  Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics.

Authors:  Margaret F Keil; Constantine A Stratakis
Journal:  Expert Rev Neurother       Date:  2008-04       Impact factor: 4.618

9.  Whole-exome sequencing studies of nonfunctioning pituitary adenomas.

Authors:  Paul J Newey; M Andrew Nesbit; Andrew J Rimmer; Rosie A Head; Caroline M Gorvin; Moustafa Attar; Lorna Gregory; John A H Wass; David Buck; Niki Karavitaki; Ashley B Grossman; Gilean McVean; Olaf Ansorge; Rajesh V Thakker
Journal:  J Clin Endocrinol Metab       Date:  2013-02-28       Impact factor: 5.958

10.  The genome-wide mutational landscape of pituitary adenomas.

Authors:  Zhi-Jian Song; Zachary J Reitman; Zeng-Yi Ma; Jian-Hua Chen; Qi-Lin Zhang; Xue-Fei Shou; Chuan-Xin Huang; Yong-Fei Wang; Shi-Qi Li; Ying Mao; Liang-Fu Zhou; Bao-Feng Lian; Hai Yan; Yong-Yong Shi; Yao Zhao
Journal:  Cell Res       Date:  2016-09-27       Impact factor: 25.617

View more
  1 in total

Review 1.  Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art.

Authors:  Tiziana Feola; Francesca Carbonara; Monica Verrico; Rosa Maria Di Crescenzo; Francesca Gianno; Claudio Colonnese; Antonietta Arcella; Dario de Alcubierre; Silverio Tomao; Vincenzo Esposito; Felice Giangaspero; Giuseppe Minniti; Marie-Lise Jaffrain-Rea
Journal:  Cancers (Basel)       Date:  2022-08-24       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.